Critical Care (journal)

EQS-News: International Experts Highlight Demand for Diagnostic Innovations as PenKid's Research and Real-World Data Fuels Quest for Improved RRT Liberation Tools

Retrieved on: 
Wednesday, September 6, 2023
Royal Surrey County Hospital, Hospice and palliative medicine, University, Consultant, E pluribus unum, RRT, Critical Care (journal), Overalls, Renal replacement therapy, Biomarker, AKI, Intensive care medicine, Acute kidney injury, CRRT, Professor, University Hospital Heidelberg, Patient, School, RICH, Mortality, University of Surrey, Intensive care unit, Health, Southern Illinois University School of Medicine, Pharmaceutical industry, Medical imaging, Nursing

Recently published scientific data affirms that penKid remains informative under acute renal replacement therapy (RRT) and can identify patients for successful liberation.

Key Points: 
  • Recently published scientific data affirms that penKid remains informative under acute renal replacement therapy (RRT) and can identify patients for successful liberation.
  • RRT, a common practice in Intensive Care Units (ICUs), has long relied on clinical observations for stop decisions.
  • However, the lack of a dependable biomarker poses challenges in accurately assessing when to discontinue RRT.
  • Considering this, leading experts from the field have discussed in a recent advisory board the importance of identifying the right tools to improve the outcomes in AKI.

EQS-News: Boditech Med and SphingoTec close Market Development Agreement to Boost Commercialization of Kidney Function Biomarker PenKid

Retrieved on: 
Thursday, August 31, 2023
Partnership, PMID, Acute kidney injury, Critical Care (journal), Hollinger, Septic shock, Risk, AKI, Kidney, Korea, Patient, Developed country, Renal replacement therapy, INT, Diagnosis, MDA, Medical device, Dietary supplement, Sepsis

In 2022, Boditech Med and SphingoTec closed a global licensing agreement to develop and offer the Proenkephalin A 119-159 (penKid) test on Boditech's automated immunoassay systems.

Key Points: 
  • In 2022, Boditech Med and SphingoTec closed a global licensing agreement to develop and offer the Proenkephalin A 119-159 (penKid) test on Boditech's automated immunoassay systems.
  • The current market development agreement aims at enhancing the commercialization of the upcoming assay for penKid and ultimately advancing AKI diagnostics.
  • Gangwon-do, Republic of Korea and Hennigsdorf/Berlin, Germany, August 31, 2023 - Boditech Med Inc. (“Boditech”) and SphingoTec GmbH (“SphingoTec”) today announced they have entered into a market development agreement (MDA), building on their previous licensing collaboration for the kidney function biomarker penKid.
  • The MDA solidifies the partnership between Boditech and SphingoTec, aiming to support the successful commercialization of the assay for the biomarker penKid on the AFIAS platforms.

EQS-News: ADQI Group Recognizes PenKid as Relevant Functional Biomarker for Sepsis-Associated Acute Kidney Injury

Retrieved on: 
Saturday, April 15, 2023
GFR, Hospice and palliative medicine, Drug development, Therapy, Sepsis, Critical Care (journal), Hollinger, Diagnosis, Glomerular filtration rate, Research, Biomarker, Septic shock, AKI, Dialysis, Incidence, Acute kidney injury, Patient, Risk, Renal replacement therapy, Kidney, Septic, Disease, Medical imaging, Pharmaceutical industry, Hospital

According to the statement, the kidney function biomarker Proenkephalin A 119-159 (penKid) can detect subclinical AKI, enabling early risk prediction for upcoming AKI.

Key Points: 
  • According to the statement, the kidney function biomarker Proenkephalin A 119-159 (penKid) can detect subclinical AKI, enabling early risk prediction for upcoming AKI.
  • Sepsis-associated acute kidney injury: consensus report of the 28th Acute Disease Quality Initiative workgroup.
  • Incidence and outcome of subclinical acute kidney injury using penKid in critically ill patients.
  • Proenkephalin A 119-159 (Penkid) is an early biomarker of septic acute kidney injury: the kidney in sepsis and septic shock (Kid-SSS) study.

EQS-News: Liberation from renal replacement therapy and early initiation to be supported by the kidney function biomarker Proenkephalin A 119-159 (penKid)

Retrieved on: 
Sunday, December 18, 2022
Acute kidney injury, Peter Bergmann case, Immunoassay, Diagnosis, Quality of life, PENK, RRT, Renal replacement therapy, Inflammation, Trial of the century, Hypertension, GFR, DOI, Sepsis, IVD, JAMA, Clinical Chemistry (journal), AKI, Prognosis, Marketing, Diabetes, Shock, Jean-Louis Vincent, Critical Care (journal), Biomarker, Precision medicine, Risk, Hoste, Hennigsdorf, Patient, Veni, vidi, vici, Medical imaging, Pharmaceutical industry, Medical device, Hospital, Phosphorus

PenKid identified as a promising kidney function biomarker to support future precision medicine approaches for RRT-dependent AKI.

Key Points: 
  • PenKid identified as a promising kidney function biomarker to support future precision medicine approaches for RRT-dependent AKI.
  • Hennigsdorf, Germany, December 15, 2022 - The diagnostic company SphingoTec GmbH (SphingoTec) announces first data on the kidney function biomarker penKid as a promising tool in supporting early initiation and liberation from RRT (1).
  • Proenkephalin A 119–159 predicts early and successful liberation from renal replacement therapy in critically ill patients with acute kidney injury: a post hoc analysis of the ELAIN trial.
  • Scientific evidence shows that penKid also reflects kidney function in children, representing a potential biomarker for pediatric AKI.

EQS-News: Boditech Med and SphingoTec close global licensing agreement for kidney function biomarker Proenkephalin A 119-159 (penKid)

Retrieved on: 
Sunday, November 27, 2022
IVD, Hypertension, Hennigsdorf, Critical Care (journal), Gangwon, Acute kidney injury, Diagnosis, AKI, Partnership, Physician, Renal replacement therapy, Patient, South Korea, Degenerative disease, Biomarker, Critical care, Glomerular filtration rate, Septic shock, Inflammation, Spectrophotometry, Diabetes, Infection, Cancer, Korea, Hollinger, Jean-Louis Vincent, GFR, Kidney, Clinical Chemistry and Laboratory Medicine, Pharmaceutical industry, Medical imaging, Hospital, Sepsis

Gangwon-do, Republic of Korea and Hennigsdorf/Berlin, Germany, November 15, 2022 - Boditech Med Inc. (Boditech) and SphingoTec GmbH (SphingoTec) today announced they have entered into a non-exclusive royalty-bearing license agreement.

Key Points: 
  • Gangwon-do, Republic of Korea and Hennigsdorf/Berlin, Germany, November 15, 2022 - Boditech Med Inc. (Boditech) and SphingoTec GmbH (SphingoTec) today announced they have entered into a non-exclusive royalty-bearing license agreement.
  • The critical state is currently diagnosed by standard-of-care biomarkers when 50% of the kidney function is already lost (1).
  • PenKid addresses these pitfalls, offering an earlier and more precise determination of kidney function in acute and critical care settings (2).
  • Proenkephalin A 119-159 (Penkid) Is an Early Biomarker of Septic Acute Kidney Injury: The Kidney in Sepsis and Septic Shock (Kid-SSS) Study.

DGAP-News: Endothelial function biomarker bioactive Adrenomedullin (bio-ADM) enables triage of sepsis patients in the emergency department

Retrieved on: 
Monday, August 1, 2022
Nexus, CA, PCT, DPP3, Infection, Diagnosis, Pheochromocytoma, Critical Care (journal), Mortality, Physician, Septic shock, Lundberg, Biomarker, Sepsis, CSO, Risk, Triage, Pharmacology, News, IVD, Endothelial dysfunction, Disease, Teaching hospital, TSH, Patient, Jean-Louis Vincent, Professor, Pathology, Lund University, Association, High-dependency unit, N-terminal prohormone of brain natriuretic peptide, ICU, Critical care, Medical imaging, Medical device, Medicine, Hennigsdorf, Troponin

Unfortunately, sepsis is difficult to diagnose and treat because it has a high range of forms and intensities.

Key Points: 
  • Unfortunately, sepsis is difficult to diagnose and treat because it has a high range of forms and intensities.
  • In ED, it is still difficult to identify sepsis patients early, and assigning the correct further treatment is thus challenging.
  • Lundberg OHM, Rosenqvist M, Bronton K, Schulte J, Friberg H, Melander O (2022) Bioactive adrenomedullin in sepsis patients in the emergency department is associated with mortality, organ failure, and admission to intensive care.
  • SphingoTec's proprietary biomarker portfolio includes bioactive Adrenomedullin (bio-ADM), a biomarker for real-time assessment of endothelial function in conditions like sepsis, and Proenkephalin (penKid), a biomarker for real-time assessment of kidney function.

Terumo Blood and Cell Technologies collaborates with Eliaz Therapeutics in the development and commercialization of a novel therapeutic apheresis treatment for acute kidney injury (AKI)

Retrieved on: 
Wednesday, July 27, 2022
Patient, National, NIH, Chronic kidney disease, CKD, International Society of Nephrology, McIntyre, Dialysis, IP, Incidence, Acute kidney injury, Hospital, Cell, Clinical trial, ICU, Death, Nephron, Critical Care (journal), International Society, SA, Fatty liver disease, Triple-negative breast cancer, Cancer, Technology, Lancet, Spectra, ROSA, Nephrology, ESRD, PLOS, GLOBE, Industry, RL, Software, Sepsis, Kidney, General manager, TSE, COVID-19, ETI, Blood, Quality of life, Survival, Neurology, Face, Plasma, J. Eliazer Stadion, Awareness, Veni, vidi, vici, Sickle cell disease, Health, TPE, Risk, Therapy, AKI, Inflammation, MD, Horizon Fuel Cell Technologies, Animal, Pharmaceutical industry, Terumo

Terumo Blood and Cell Technologies specializes in a portfolio of technology, software and services for blood component collection, therapeutic apheresis and cellular technologies.

Key Points: 
  • Terumo Blood and Cell Technologies specializes in a portfolio of technology, software and services for blood component collection, therapeutic apheresis and cellular technologies.
  • Working with Terumo Blood and Cell Technologies could bring broad availability of this therapy to the global marketplace."
  • Terumo Blood and Cell Technologies' customers include blood centers, hospitals, therapeutic apheresis clinics, cell collection and processing organizations, researchers and private medical practices.
  • Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology.